SCHEMBL16668447

SCHEMBL16668447

Clc1ncc(Cl)c(OC2CCOC2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 2/20 0.42
LRRK2 Q5S007 4/20 0.41
CNR2 P34972 2/20 0.41
CNR1 P21554 1/20 0.41
TYK2 P29597 3/20 0.37
AKT1 P31749 1/20 0.36
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
GRM5 P41594 2/20 0.35
GRM4 Q14833 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
PDE2A O00408 1/20 0.35
PDE10A Q9Y233 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4535316 0.90 LRRK2 (0.42) FGFR4LRRK2GRM4
SCHEMBL5021108 0.89 CNR2 (0.34) FGFR4LRRK2CNR2CNR1GRM5
SCHEMBL1031892 0.87 LRRK2 (0.39) FGFR4LRRK2CNR2CNR1TYK2
SCHEMBL1983054 0.87 POLB (0.41) LRRK2CNR2CNR1TYK2GRM5
SCHEMBL1031891 0.87 LRRK2 (0.39) FGFR4LRRK2CNR2CNR1TYK2
SCHEMBL16668004 0.85 AKT1 (0.45) FGFR4LRRK2CNR2CNR1TYK2
SCHEMBL16668468 0.85 AKT1 (0.45) FGFR4LRRK2CNR2CNR1TYK2
SCHEMBL22895691 0.83 HDAC3 (0.38) LRRK2
SCHEMBL6496656 0.83 CNR1 (0.51) FGFR4LRRK2CNR2CNR1TYK2
SCHEMBL2062123 0.77 HTR1A (0.43) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3060563-B1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2018-05-02 EP disclosed
US-9896449-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2018-02-20 US disclosed
US-20170066766-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2017-03-09 US disclosed
US-9533988-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2017-01-03 US disclosed
EP-3060563-A1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS Novartis AG (CH) 2016-08-31 EP disclosed
US-20160102092-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2016-04-14 US disclosed
US-9266883-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2016-02-23 US disclosed
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2015-04-30 US disclosed
WO-2015059668-A1 RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 FGFR4 1/4885LRRK2 569/4885CNR2 1951/4885
US-20160102092-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 FGFR4 1/4885LRRK2 569/4885CNR2 1951/4885
US-20170066766-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 FGFR4 1/4885LRRK2 569/4885CNR2 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.